• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Donald S. Kaufman, MD


  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder.N Engl J Med. 2013 Aug 15;369(7):660-7.
  • Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL.Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.Lancet Oncol. 2013 Aug;14(9):863-72.
  • Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB.Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.Hum Pathol. 2013 May;44(5):860-6.
  • Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU.Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.Int J Radiat Oncol Biol Phys. 2013 Mar 5.
  • Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL.Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.Current Urology Reports. 2013 Apr;14(2):109-15.
  • Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G.Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma.Clin Genitourin Cancer. 2013 Jan 15.
  • Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer.N Engl J Med. 2011 Feb 17;364(7):667-75.
  • Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.J Urol. 2010 Jun;183(6):2200-5.
  • Kaufman DS, McDougal WS, Harisinghani MG, Wu CL.Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.N Engl J Med. 2009 Sep 24;361(13):1292-9.
  • Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM.Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.J Clin Oncol. 2009 Sep 1;27(25):4055-61.
  • Kaufman DS, Shipley WU, Feldman AS.Bladder cancer.Lancet. 2009 Jul 18;374(9685):239-49. Review.
  • Wo JY,Shipley WU,Dahl DM,Coen JJ,Heney NM,Kaufman DS,Zietman AL.The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?.BJU Int. 2009 Jul;104(2):179-83.
  • Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M.Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy.Clin Imaging.;33(4):301-5.
  • Heney NM,Kaufman DS,Shipley WU.Surgery: selective bladder-preserving therapy for muscle-invasive cancer.Nat Rev Clin Oncol. 2009 Apr;6(4):193-4. Review.
  • Kaufman DS,Winter KA,Shipley WU,Heney NM,Wallace HJ 3rd,Toonkel LM,Zietman AL,Tanguay S,Sandler HM.Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.Urology. 2009 Apr;73(4):833-7.
  • Mak RH,Zietman AL,Heney NM,Kaufman DS,Shipley WU.Bladder preservation: optimizing radiotherapy and integrated treatment strategies.BJU Int. 2008 Nov;102(9 Pt B):1345-53. Review.
  • Barry MJ,Kaufman DS,Wu CL.Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.N Engl J Med. 2008 May 15;358(20):2161-8.
  • Woll PS, Morris JK, Painschab MS, Marcus RK, Kohn AD, Biechele TL, Moon RT, Kaufman DS.Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells.Blood. 2008 Jan 1;111(1):122-31.
  • Kaufman DS, McDougal WS, Zietman AL, Young RH.Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer.N Engl J Med. 2007 Jun 14;356(24):2515-20.
  • Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.J Clin Oncol. 2007 Mar 20;25(9):1038-42.
  • Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR.Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.Cancer. 2006 Aug 1;107(3):530-5.
  • Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, Peacock S, Symons M, Amamoo MA, Carpenter WR, Godley PA.Racial differences in clinical progression among medicare recipients after treatment for localized prostate cancer (United States).Cancer Causes Control. 2006 Aug;17(6):803-11.
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
  • Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.Clin Cancer Res. 2005 Jan 1;11(1):284-9.
  • Kaufman DS, McDougal WS, Zietman AL, Harisinghani MG, Young RH.Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy.N Engl J Med. 2004 Jul 8;351(2):171-8.
  • Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS.Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder.Br J Cancer. 2004 Feb 9;90(3):578-81.
  • Kaufman DS, Shipley WU, McDougal WS, Young RH.Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladder.N Engl J Med. 2004 Jan 22;350(4):394-402.
  • Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS.Selective Bladder Preservation for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder.Br J Cancer. 2004;in press:00-00.
  • Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.Urology. 2003 Jul;62(1):99-104.
  • Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW.Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.Am J Clin Oncol. 2003 Jun;26(3):312-6.
  • Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK.Male patients with diagnoses of both breast cancer and prostate cancer.Breast J. 2003 May-Jun;9(3):208-12.
  • Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW.Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.Cancer. 2002 Nov 1;95(9):1864-8.
  • Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL.Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.Urology. 2002 Jul;60(1):62-7; discussion 67-8.
  • Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR.A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.Cancer Invest. 2002;20(2):186-91.
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5.
  • Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS.Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer?.Cancer J Sci Am. 1999 Jul-Aug;5(4):242-7.
  • Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL.An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.J Urol. 1999 Aug;162(2):445-50; discussion 450-1.
  • Chakravarti A, Compton CC, Shellito PC, Wood WC, Landry J, Machuta SR, Kaufman D, Ancukiewicz M, Willett CG.Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation.Ann Surg. 1999 Jul;230(1):49-54.
  • Nakfoor BM, Willett CG, Shellito PC, Kaufman DS, Daly WJ.The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer.Ann Surg. 1998 Aug;228(2):194-200.
  • Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT.Selective bladder preservation by combination treatment of invasive bladder cancer.N Engl J Med. 1993 Nov 4;329(19):1377-82.